JP2008500281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500281A5 JP2008500281A5 JP2007501804A JP2007501804A JP2008500281A5 JP 2008500281 A5 JP2008500281 A5 JP 2008500281A5 JP 2007501804 A JP2007501804 A JP 2007501804A JP 2007501804 A JP2007501804 A JP 2007501804A JP 2008500281 A5 JP2008500281 A5 JP 2008500281A5
- Authority
- JP
- Japan
- Prior art keywords
- absent
- peptide
- hse
- calcitonin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 229910052731 fluorine Inorganic materials 0.000 claims 18
- 229910052720 vanadium Inorganic materials 0.000 claims 16
- 229910052740 iodine Inorganic materials 0.000 claims 15
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 14
- 229910052700 potassium Inorganic materials 0.000 claims 13
- 229910052727 yttrium Inorganic materials 0.000 claims 12
- 102000055006 Calcitonin Human genes 0.000 claims 10
- 108060001064 Calcitonin Proteins 0.000 claims 10
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 10
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 10
- 229960004015 calcitonin Drugs 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 229910052698 phosphorus Inorganic materials 0.000 claims 10
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 7
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 6
- 208000008279 Dumping Syndrome Diseases 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 206010022489 Insulin Resistance Diseases 0.000 claims 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 208000032395 Post gastric surgery syndrome Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000001352 cholecystitis Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 208000004104 gestational diabetes Diseases 0.000 claims 4
- 208000019622 heart disease Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 201000001421 hyperglycemia Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 201000002859 sleep apnea Diseases 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000001212 derivatisation Methods 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 2
- 229960002591 hydroxyproline Drugs 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108010068072 salmon calcitonin Proteins 0.000 claims 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54327504P | 2004-02-11 | 2004-02-11 | |
| US55044704P | 2004-03-04 | 2004-03-04 | |
| PCT/US2005/004631 WO2006083254A1 (en) | 2004-02-11 | 2005-02-11 | Amylin family peptides and methods for making and using them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008500281A JP2008500281A (ja) | 2008-01-10 |
| JP2008500281A5 true JP2008500281A5 (enExample) | 2008-03-13 |
Family
ID=34963236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501804A Pending JP2008500281A (ja) | 2004-02-11 | 2005-02-11 | アミリンファミリーペプチドおよびそれらを作成し使用するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8114958B2 (enExample) |
| EP (2) | EP2233497A3 (enExample) |
| JP (1) | JP2008500281A (enExample) |
| KR (1) | KR101196122B1 (enExample) |
| AT (1) | ATE471340T1 (enExample) |
| AU (2) | AU2005320351B2 (enExample) |
| BR (1) | BRPI0507623A (enExample) |
| CA (1) | CA2556226A1 (enExample) |
| DE (1) | DE602005021858D1 (enExample) |
| ES (1) | ES2345113T3 (enExample) |
| IL (2) | IL177230A0 (enExample) |
| NZ (2) | NZ571824A (enExample) |
| RU (1) | RU2385878C2 (enExample) |
| WO (1) | WO2006083254A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| JP2008500281A (ja) * | 2004-02-11 | 2008-01-10 | アミリン・ファーマシューティカルズ，インコーポレイテッド | アミリンファミリーペプチドおよびそれらを作成し使用するための方法 |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| ES2325773T5 (es) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
| DK1888094T3 (da) | 2005-03-31 | 2009-11-09 | Amylin Pharmaceuticals Inc | Amylin og amylinagonister til behandling af psykiatriske sygdomme og forstyrrelser |
| US8309522B2 (en) | 2007-02-05 | 2012-11-13 | Amylin Pharmaceuticals, Llc | Neuromedin and FN-38 peptides for treating psychiatric diseases |
| US20110152183A1 (en) * | 2008-06-25 | 2011-06-23 | Novo Nordisk A/S | Derivatised hybrid peptides of amylin and salmon calcitonin |
| US20110201022A1 (en) * | 2008-07-30 | 2011-08-18 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| BRPI1006943A2 (pt) * | 2009-01-22 | 2021-06-15 | Unigene Laboratories Inc. | peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes |
| JP5993147B2 (ja) * | 2009-03-12 | 2016-09-14 | キーバイオサイエンス・アクチエンゲゼルシャフト | 糖尿病およびメタボリックシンドロームの治療 |
| WO2010107874A2 (en) | 2009-03-17 | 2010-09-23 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition using amylin agonists |
| WO2010118384A2 (en) | 2009-04-10 | 2010-10-14 | Amylin Pharmaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
| WO2011063414A1 (en) | 2009-11-23 | 2011-05-26 | Amylin Pharmaceuticals, Inc. | Polypeptide conjugate |
| GB201001333D0 (en) | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| EP2531209B1 (en) * | 2010-02-04 | 2016-04-20 | BioMarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof |
| EA024507B1 (ru) | 2010-09-28 | 2016-09-30 | Амилин Фармасьютикалс, Ллк | Хорошо растворимые лептины |
| EP3028720A1 (en) | 2010-09-28 | 2016-06-08 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action |
| US9694051B2 (en) | 2011-04-07 | 2017-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Long-acting peptide analogs |
| WO2012160212A1 (en) | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
| EP2714069A4 (en) | 2011-05-25 | 2015-06-24 | Amylin Pharmaceuticals Llc | LONG-TERM CONJUGATES WITH TWO HORMONES |
| JP2014516049A (ja) * | 2011-05-25 | 2014-07-07 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | アミリンペプチドおよび誘導体ならびにそれらの使用 |
| DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
| CN104271588B (zh) | 2011-07-08 | 2017-10-10 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
| WO2013059336A1 (en) * | 2011-10-18 | 2013-04-25 | Amylin Pharmaceuticals, Llc | Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties |
| MX351092B (es) | 2011-11-02 | 2017-10-02 | Keybioscience Ag | Analogos peptidicos para tratar enfermedades y trastornos. |
| US9533022B2 (en) | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
| ES2819825T3 (es) | 2012-01-26 | 2021-04-19 | Soares Christopher J | Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso |
| EP2841089A4 (en) | 2012-04-03 | 2016-03-16 | Univ Boston | COMPOSITIONS, PROCESSES AND ASSAYS WITH AMYLIN OR AMLYANANALOGA FOR ABETA PEPTIDE-MEDIATED ILLNESSES |
| US8575091B1 (en) | 2012-04-19 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
| EP3027644B1 (en) * | 2013-07-30 | 2019-08-21 | Christopher J. Soares | Cgrp agonist peptides |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR103954A1 (es) | 2015-03-18 | 2017-06-14 | Zealand Pharma As | Análogos de amilina |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
| CN116063580A (zh) | 2016-01-04 | 2023-05-05 | 艾得佩索拉公司 | 肽类似物 |
| WO2017139154A1 (en) | 2016-02-09 | 2017-08-17 | Adepthera Llc | Dosing and use of long-acting clr/ramp agonists |
| EP4316595A3 (en) | 2016-09-02 | 2024-04-17 | Christopher J. Soares | Use of cgrp receptor antagonists in treating glaucoma |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| WO2019005623A1 (en) | 2017-06-30 | 2019-01-03 | Adepthera Llc | PEPTIDE ANALOGS |
| EP3474820B1 (en) | 2017-08-24 | 2024-02-07 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| WO2021056106A1 (en) | 2019-09-23 | 2021-04-01 | Dds Research Inc. | Lipid vesicle compositions with penetration enhancing agents |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| KR20240035939A (ko) * | 2021-03-24 | 2024-03-19 | 글로 파마, 인크. | 피부 색소침착을 감소시키기 위한 펩타이드 및 방법 |
| WO2024189611A1 (en) * | 2023-03-13 | 2024-09-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Stabilized analogues of calcitonin |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| GB8720115D0 (en) * | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
| GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| EP0719860B1 (en) | 1988-05-13 | 2009-12-16 | Amgen Inc. | Process for isolating and purifying G-CSF |
| US5264372A (en) | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| US5580953A (en) * | 1991-08-14 | 1996-12-03 | Amylin Pharmaceuticals, Inc. | Amylin antagonist peptides and uses therefor |
| US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| JPH06256210A (ja) * | 1993-03-10 | 1994-09-13 | Hoechst Japan Ltd | 骨関連転写制御因子様タンパク質およびその製造法 |
| HUT70176A (en) | 1993-05-12 | 1995-09-28 | Univ Cincinnati | Amylin antagonists and agonists |
| DE69426304T2 (de) * | 1993-09-07 | 2001-03-15 | Amylin Pharmaceuticals, Inc. | Methoden zur regulation der den magen und darm betreffenden motilitaet |
| US5766627A (en) * | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
| US5686511A (en) | 1996-06-28 | 1997-11-11 | The Valspar Corporation | Esterifying epoxy resin with carboxyl polymer and quenching |
| US5677279A (en) | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
| EP1629849B2 (en) | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmaceutical compositions comprising exendins and agonists thereof |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US7101853B2 (en) | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
| US20040022807A1 (en) * | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
| US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| CA2299425A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
| NZ504258A (en) | 1997-11-14 | 2002-12-20 | Amylin Pharmaceuticals Inc | Exendin 3 and 4 agonist compounds for the treatment of diabetes |
| PT1032587E (pt) | 1997-11-14 | 2008-04-21 | Amylin Pharmaceuticals Inc | Novos compostos agonistas de exendina |
| US6936584B1 (en) * | 1998-02-13 | 2005-08-30 | Amylin Pharmaceuticals, Inc. | Mixed amylin activity compounds |
| JP4372345B2 (ja) * | 1998-02-13 | 2009-11-25 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 新規な混合アミリン活性化合物 |
| US6087334A (en) * | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| US6194006B1 (en) * | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| RU2166258C2 (ru) * | 1999-07-01 | 2001-05-10 | Общество с ограниченной ответственностью Научно-производственный центр "Витиус" | Композиция фиточая |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US6264987B1 (en) * | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| US6296842B1 (en) * | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| US20030026182A1 (en) * | 2001-08-06 | 2003-02-06 | Fischer Michael C. | Method and system for write clock synchronization in a data storage system |
| ES2425221T3 (es) * | 2003-05-30 | 2013-10-14 | Amylin Pharmaceuticals, Llc | Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas |
| EP2417980A1 (en) * | 2004-02-11 | 2012-02-15 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
| JP2008500281A (ja) * | 2004-02-11 | 2008-01-10 | アミリン・ファーマシューティカルズ，インコーポレイテッド | アミリンファミリーペプチドおよびそれらを作成し使用するための方法 |
| US8603969B2 (en) * | 2004-02-11 | 2013-12-10 | Amylin Pharmaceuticals, Llc | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| EP2360180A3 (en) | 2004-12-13 | 2012-02-08 | Amylin Pharmaceuticals Inc. | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| DK1888094T3 (da) * | 2005-03-31 | 2009-11-09 | Amylin Pharmaceuticals Inc | Amylin og amylinagonister til behandling af psykiatriske sygdomme og forstyrrelser |
-
2005
- 2005-02-11 JP JP2007501804A patent/JP2008500281A/ja active Pending
- 2005-02-11 CA CA002556226A patent/CA2556226A1/en not_active Abandoned
- 2005-02-11 AU AU2005320351A patent/AU2005320351B2/en not_active Ceased
- 2005-02-11 NZ NZ571824A patent/NZ571824A/en not_active IP Right Cessation
- 2005-02-11 NZ NZ549332A patent/NZ549332A/en not_active IP Right Cessation
- 2005-02-11 EP EP10006105A patent/EP2233497A3/en not_active Withdrawn
- 2005-02-11 EP EP05723040A patent/EP1716172B1/en not_active Expired - Lifetime
- 2005-02-11 DE DE602005021858T patent/DE602005021858D1/de not_active Expired - Lifetime
- 2005-02-11 RU RU2006132293/13A patent/RU2385878C2/ru not_active IP Right Cessation
- 2005-02-11 WO PCT/US2005/004631 patent/WO2006083254A1/en not_active Ceased
- 2005-02-11 BR BRPI0507623-4A patent/BRPI0507623A/pt not_active IP Right Cessation
- 2005-02-11 US US10/589,054 patent/US8114958B2/en not_active Expired - Fee Related
- 2005-02-11 ES ES05723040T patent/ES2345113T3/es not_active Expired - Lifetime
- 2005-02-11 AT AT05723040T patent/ATE471340T1/de not_active IP Right Cessation
-
2006
- 2006-08-02 IL IL177230A patent/IL177230A0/en unknown
- 2006-09-08 KR KR1020067018379A patent/KR101196122B1/ko not_active Expired - Fee Related
-
2009
- 2009-12-17 IL IL202795A patent/IL202795A0/en unknown
-
2010
- 2010-08-20 AU AU2010212468A patent/AU2010212468A1/en not_active Ceased
-
2012
- 2012-02-01 US US13/364,250 patent/US8598120B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008500281A5 (enExample) | ||
| RU2006132293A (ru) | Пептиды семейства амилинов и способы их получения и применения | |
| CA2320371A1 (en) | Inotropic and diuretic effects of exendin and glp-1 | |
| AR038102A1 (es) | Analogos extendidos de peptido 1 de tipo glucagon | |
| JP2019504055A5 (enExample) | ||
| JP2005534647A5 (enExample) | ||
| EP2422808A3 (en) | Novel compounds and their effects on feeding behaviour | |
| JP2009529553A5 (enExample) | ||
| CA2412004A1 (en) | Glucagon-like peptide-1 analogs | |
| JP2019504057A5 (enExample) | ||
| AU2025248685A1 (en) | Co-agonists of the GLP-1 and amylin receptors | |
| PE20250556A1 (es) | Agonista triple de receptores de glucagon/glp-1/gip | |
| HRP20100062T1 (hr) | Glp-1 (glukagon-like peptid-1) fuzijski polipeptidi sa povećanom otpornošću na peptidaze | |
| PE20240890A1 (es) | Moduladores de los receptores acoplados a proteinas g | |
| JPWO2022129526A5 (enExample) | ||
| CN101939022A (zh) | 治疗肥胖以及肥胖相关疾病和病症的方法 | |
| CZ2004441A3 (cs) | Léčivo pro snižování mortality a morbidity souvisejících s kritickými onemocněními | |
| UA102370C2 (ru) | Пептид, фармацевтическая композиция и лекарственное средство, которое его содержит, способ лечения и/или предупреждения диабета и сопутствующих ожирению заболеваний, способ снижения аппетита, снижение поглощения пищи и снижение массы тела | |
| JP2020500163A5 (enExample) | ||
| JPWO2022129254A5 (enExample) | ||
| DE60306771D1 (de) | Neue peptidzusammensetzungen und deren verwendung, insbesondere zur herstellung von pharmazeutischen zusammensetzungen mit wirkung gegen das hepatitis-c-virus | |
| RU2025117213A (ru) | Аналоги амилина | |
| GB2640988A (en) | Amylin analogues | |
| JPWO2021215801A5 (enExample) | ||
| US20250074964A1 (en) | Stable glp-1 analogs for the treatment of human disease and disorders |